Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing CapabilitiesOramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology.HTIT to invest $60 million, Oramed to invest $15 million into OraTech.HTIT to provide a supply agreement for oral insulin capsules.New Phase 3 trial in the U.S. with a revised protocol expected to begin this quarter.OraTech to advance registration of oral insulin in the U.S. and other countries.OraTech to receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted, and commercialization preparations are underway by HTIT.NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the de
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- Oramed Pharmaceuticals (NASDAQ:ORMP) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oramed Reports Fiscal Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Oramed Reports Fiscal Third Quarter 2025 Financial ResultsPR Newswire
- ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSPR Newswire
- Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives [Yahoo! Finance]Yahoo! Finance
ORMP
Earnings
- 11/13/25 - Beat
ORMP
Sec Filings
- 11/17/25 - Form 8-K
- 11/17/25 - Form 8-A12B
- 11/17/25 - Form 8-K
- ORMP's page on the SEC website